For personal use only - Australian Securities Exchange

For personal use only
MARKET RELEASE
24 October 2014
Clinuvel Pharmaceuticals Ltd
TRADING HALT
The securities of Clinuvel Pharmaceuticals Ltd (the “Company”) will be placed in
Trading Halt Session State at the request of the Company, pending the release of an
announcement by the Company. Unless ASX decides otherwise, the securities will
remain in Trading Halt Session State until the earlier of the commencement of
normal trading on Tuesday, 28 October 2014 or when the announcement is released
to the market.
Security Code:
CUV
Kobe Li
Senior Adviser, Listings Compliance (Melbourne)
24th October 2014
For personal use only
Mr James Gerraty
Manager Listings, Melbourne
Level 45, Rialto South Tower
525 Collins Street, Melbourne VIC 3000
By email: [email protected]
Dear Mr Gerraty,
Re: REQUEST FOR TRADING HALT
Pursuant to Listing Rule 17.1, Clinuvel Pharmaceuticals Ltd (CUV) requests an immediate trading halt
with respect to its ordinary shares listed on the ASX.
The trading halt is necessary as CUV proposes to make an announcement to the market regarding the
outcome of the review of a marketing authorisation application (MAA) for CUV’s drug SCENESSE® for
the treatment of erythropoeitic protoporphria (EPP) by the European Medicines Agency (EMA). The
EMA’s Committee for Medicinal Products for Human Use (CHMP) held its October plenary meeting in
London which concluded overnight. During this meeting the CHMP was expected to make a final
recommendation regarding the MAA for SCENESSE®. Any decision on the SCENESSE® MAA will be
included in the highlights to the meeting which may be published by the EMA approximately midday
today (UK time).
CUV requests the trading halt to last until the earlier of CUV releasing an announcement in relation to
the outcome to the review process, expected on the morning of Monday 27th October 2014, or until the
commencement of trade on Tuesday 28th October 2014.
CUV is not aware of any reason why the trading halt should not be granted by the ASX nor is it aware of
any other information that is necessary to inform the market about the trading halt.
Yours faithfully,
Darren Keamy
Company Secretary
Clinuvel Pharmaceuticals Ltd
Australian Office: Level 14, 190 Queen Street Melbourne Victoria 3000 Australia T +61 3 9660 4900
European Office: Neuhofstrasse 3D, 6340 Baar, Switzerland T +41 41 767 4545
US Office: 40 Worth Street, Suite 1053, Floor 10 New York, NY 10013, USA T +1 646 527 7310
Singapore Office: 9 Temasek Boulevard, #29-01, Singapore 038989 T +65 315 751 34
www.clinuvel.com

Download Report